Safety and efficacy of durvalumab with R-CHOP or R

Autor: Grzegorz S, Nowakowski, Wolfgang, Willenbacher, Richard, Greil, Thomas S, Larsen, Krish, Patel, Ulrich, Jäger, Robert F, Manges, Lorenz, Trümper, Hele, Everaus, Nagesh, Kalakonda, Peter, Brown, Judit Meszaros, Jørgensen, David, Cunningham, Justine, Dell'Aringa, Brian, Fox, Neus Domper, Rubio, Nurgul, Kilavuz, Marie-Laure, Casadebaig, Oliver, Manzke, Javier, Munoz

Publikováno v: International journal of hematology. 115(2)

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f76e145dd7db709f9b97d2287b4265fc
https://pubmed.ncbi.nlm.nih.gov/34797531

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Autor: Pierre W. Wijermans, Hong Xie, Peter M. Voorhees, Richard C. Frank, Robert Z. Orlowski, Brett Hall, Britte Kranenburg, Helgi van de Velde, Amrita Krishnan, Xiang Qin, Sonja Zweegman, Robert F. Manges, Sundar Jagannath, George Somlo, Tineke Casneuf, Suzanne Lentzsch, Sheeba K. Thomas, Pieter Sonneveld

Publikováno v: British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 161(3), 357-366. Wiley-Blackwell
Voorhees, P M, Manges, R F, Sonneveld, P, Jagannath, S, Somlo, G, Krishnan, A, Lentzsch, S, Frank, R C, Zweegman, S, Wijermans, P W, Orlowski, R Z, Kranenburg, B, Hall, B, Casneuf, T, Qin, X, te Velde, H, Xie, H & Thomas, S K 2013, ' A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma ', British Journal of Haematology, vol. 161, no. 3, pp. 357-366 . https://doi.org/10.1111/bjh.12266

Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f4d4f74a2ddb95ff667d1cdffe50470
https://pure.eur.nl/en/publications/0520724d-84ac-4d5c-8ab7-27c36ead6b9c

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Autor: Sundar Jagannath, Ravi Vij, Jeffrey A. Zonder, Eric Bleickardt, Prashni Paliwal, Mark Lynch, Ashraf Badros, Jonathan L. Kaufman, Jesus G. Berdeja, Robert F. Manges

Publikováno v: Blood. 124:2119-2119

INTRODUCTION Renal impairment affects more than a third of patients with relapsed multiple myeloma (MM). Renal impairment predicts poor outcome with conventional treatments, while reversal of renal function is associated with improved outcome.1,2 Bet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27bf44f21d9c60bc55b495ef95e32c00
https://doi.org/10.1182/blood.v124.21.2119.2119

Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients

Autor: Ian W. Flinn, Thomas A. Warr, Vijay R. Phooshkooru, Christopher H. Chay, Robert M. Rifkin, James A. Reeves, Billy Clowney, Ruben Niesvizky, Veena Charu, Nashat Y. Gabrail, Deyanira Corzo, Rachel Neuwirth, Robert F. Manges

Publikováno v: Blood. 114:129-129

Abstract 129 In this US community-based, randomized, open-label, multicenter phase 3b study, we compare the safety and efficacy of three highly active bortezomib (Velcade®, Vc)-based regimens for multiple myeloma (MM), Vc–thalidomide–dexamethaso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a710d194f4e3978e2072ce9427ab274
https://doi.org/10.1182/blood.v114.22.129.129

Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

Autor: Robert F. Manges, Heather J. Sutherland, Sundar Jagannath, Robert Z. Orlowski, David La Police, Mark DeWitte, Zhihui Lang, Robert E. Corringham, Jean Francois Rossi

Publikováno v: Blood. 110:1183-1183

Background: Bortezomib represents a significant advance in the treatment of relapsed/refractory myeloma, but its efficacy is limited by a number of resistance mechanisms including activation of the anti-apoptotic heat shock protein (HSP) and stress r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0070bb5401debc5d783c6739723d291a
https://doi.org/10.1182/blood.v110.11.1183.1183